What to know about federal court ruling blocking mailing of widely used abortion pill
PBS • • nation
Key Points:
- A federal appeals court in New Orleans has blocked the mailing of mifepristone prescriptions, requiring the drug to be distributed only in person at clinics, overruling FDA regulations and restricting access to a common abortion method.
- The unanimous ruling by the 5th U.S. Circuit Court of Appeals is a major victory for abortion opponents and affects all states, even those without abortion restrictions, as it challenges the FDA’s authority on drug distribution.
- The decision stems from a lawsuit by Louisiana’s Attorney General, who argued the FDA’s rules undermine state abortion bans, and the ruling is expected to be appealed to the U.S. Supreme Court.
- Mifepristone, approved in 2000 and considered safe and effective, is typically used with misoprostol to end early pregnancies, with a significant portion of U.S. abortions conducted via telehealth prescriptions of these pills.
- The ruling may influence the 2024 midterm elections by intensifying abortion as a political issue, with abortion-rights advocates condemning the decision as contrary to science and public opinion.
